Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy

BackgroundSelinexor, a first-in-class, oral exportin-1 inhibitor, showed activity in penta-refractory multiple myeloma (MM) in early trial exploration; however, the side-effect profile of twice-weekly dosing led to hesitant incorporation into widespread practice. Here, our objective is to provide up...

全面介紹

書目詳細資料

發表在:	Frontiers in Oncology
Main Authors:	Muhamed Baljevic, Gary Schiller, Tomer M. Mark, Dane R. Van Domelen, Cristina Gasparetto
格式:	Article
語言:	英语
出版:	Frontiers Media S.A. 2025-09-01
主題:	selinexor multiple myeloma drug administration schedules exportin 1 antagonists inhibitors
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1649493/full